Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises 1Vision Biogas on its public offer for Biokraft
Mandate

Vinge advises 1Vision Biogas on its public offer for Biokraft

February 05, 2024 Capital Markets and Public M&A M&A FDI EU, Competition and Regulatory

1Vision Biogas AB, a company controlled by Aneo, HitecVision and St1, has made a public mandatory bid for all shares in Biokraft International AB. The offer values the shares of Biokraft at approximately SEK 900 million. Vinge advises 1Vision Biogas.

The Vinge team includes Christian Lindhé, Erik Sjöman, Martin Madsen Svanberg, Johan Åhman and Johan Severinsson (Capital Markets and Public M&A), Jesper Ottergren (M&A) as well as Sofie Nordgren, Pär Remnelid, Rikard Azelius and Jasmine Elgh (FDI/EU, Competition and Regulatory).

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026